Our current findings suggest that ErbB2 transmembrane mutations (like neu (rat) and the human 655 polymorphism) synergize with decreased/lost PTPN13, allowing breast cancer progression via a mechanism involving increased ErbB2/EphrinB1 signaling. This evidence concerns the gene ERBB2 and breast cancer.